Mateon Therapeutics (MATN) and Aevi Genomic Medicine (GNMX) Financial Survey
Mateon Therapeutics (NASDAQ: MATN) and Aevi Genomic Medicine (NASDAQ:GNMX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.
Institutional & Insider Ownership
8.6% of Mateon Therapeutics shares are owned by institutional investors. Comparatively, 20.8% of Aevi Genomic Medicine shares are owned by institutional investors. 2.3% of Mateon Therapeutics shares are owned by insiders. Comparatively, 15.2% of Aevi Genomic Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Mateon Therapeutics and Aevi Genomic Medicine’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Mateon Therapeutics||N/A||N/A||-$14.59 million||($0.54)||-0.46|
|Aevi Genomic Medicine||N/A||N/A||-$37.80 million||($1.02)||-1.62|
Aevi Genomic Medicine is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current recommendations for Mateon Therapeutics and Aevi Genomic Medicine, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aevi Genomic Medicine||0||1||1||0||2.50|
Mateon Therapeutics currently has a consensus target price of $2.00, indicating a potential upside of 696.81%. Aevi Genomic Medicine has a consensus target price of $4.25, indicating a potential upside of 157.58%. Given Mateon Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Mateon Therapeutics is more favorable than Aevi Genomic Medicine.
Volatility and Risk
Mateon Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, Aevi Genomic Medicine has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.
This table compares Mateon Therapeutics and Aevi Genomic Medicine’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aevi Genomic Medicine||N/A||-125.94%||-106.93%|
Mateon Therapeutics beats Aevi Genomic Medicine on 6 of the 10 factors compared between the two stocks.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Receive News & Ratings for Mateon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.